Introduction
============

Histamine released from mast cells and basophils initiates inflammatory responses, notably in the vasculature where its most immediate effects are dilatation of small vessels causing increased blood flow to sites of injury. These effects are mediated primarily by H~1~ histamine receptors on endothelial cells, which stimulate Gq and thereby phospholipase C (PLC) (Hill *et al*., [@b21]; Jones and Kearns, [@b24]). In larger vessels, including human arteries, H~1~ receptors directly stimulate contraction (Toda, [@b46]) and proliferation of vascular smooth muscle (VSM) cells (Satoh *et al*., [@b39]). There are, however, differences between species in the effects of histamine on the vasculature (Wang *et al*., [@b49], and references therein).

Inflammation plays a key role in the development of atherosclerosis (Hansson, [@b20]; Swedenborg *et al*., [@b42]). Atherosclerotic lesions in human aorta are associated with enhanced local synthesis of histamine and increased expression of H~1~ receptors (Takagishi *et al*., [@b43]; Tanimoto *et al*., [@b44]). Furthermore, in animal models, prevention of histamine synthesis (Toda, [@b46]; Sasaguri *et al*., [@b38]) or competitive antagonists of H~1~ receptors (Miyazawa *et al*., [@b28]) reduce intimal thickening after vascular injury. These observations implicate H~1~ receptors of VSM in both inflammatory responses and the development of atherosclerosis and restenosis.

Prostaglandin E~2~ (PGE~2~), the most abundant PG in humans, is another inflammatory mediator with widespread effects that include regulation of blood vessels (Norel, [@b31]). Human VSM synthesizes PGE~2~ (Soler *et al*., [@b40]), and its synthesis is much increased in diseased human aorta (Bayston *et al*., [@b4]). PGE~2~ is associated with development of atherosclerosis (Gomez-Hernandez *et al*., [@b18]), and EP receptors are potential targets for its treatment (Yang *et al*., [@b52]). The effects of PGE~2~ are predominantly mediated by four classes of GPCRs. EP~1~ receptors stimulate PLC via Gq, EP~2~ and EP~4~ receptors stimulate adenylyl cyclase (AC) via Gs, and most splice variants of EP~3~ receptors regulate Gi (Norel, [@b31]; Sugimoto and Narumiya [@b41]). There is evidence, albeit rather sparse in humans, suggesting that all four EP receptor subtypes are expressed in various VSM (Coleman *et al*., [@b13]; see references in Breyer *et al*., [@b11]) including EP~2~ and EP~3~ receptors in human aortic smooth muscle (Bayston *et al*., [@b4]). Activation of EP~1~, or more often EP~3~, receptors causes contraction of various VSM (Jadhav *et al*., [@b23]; Jones and Woodward, [@b26]; Kobayashi *et al*., [@b27]) including human veins (Walch *et al*., [@b48]) and arteries (Qian *et al*., [@b35]; Jones *et al*., [@b25]; references in Walch *et al*., [@b48]). Stimulation of EP~2~ or EP~4~ receptors causes relaxation of many VSM (Jones *et al*., [@b25]; Yang *et al*., [@b51]), including human vessels (Qian *et al*., [@b35]; Davis *et al*., [@b14]; Foudi *et al*., [@b15]). These responses are consistent with the common observation that PLC-coupled receptors generally cause Ca^2+^-mediated contraction of smooth muscle, including VSM, while those that stimulate AC cause relaxation (references in Roscioni *et al*., [@b36]). The latter is widely thought to be mediated by cyclic AMP-dependent protein kinase, which via phosphorylation, can attenuate Ca^2+^ signalling and/or reduce the sensitivity of the contractile apparatus to Ca^2+^ (references in Roscioni *et al*., [@b36]). Collectively, these observations suggest that PGE~2~ and EP receptors play important roles in the normal physiology of blood vessels, and they are implicated in various pathological states including atherosclerosis (Yang *et al*., [@b52]).

The possibility that H~1~ and/or EP receptors might be targeted for treatment of vascular diseases is attractive because H~1~ receptor antagonists (Hill *et al*., [@b21]) and PG analogues (Abramovitz *et al*., [@b1]; Norel, [@b31]) are already established in clinical practice for other indications. Our choice of cultured VSM to investigate interactions between histamine and PGE~2~ is vindicated by the experimental opportunities that would not be accessible in studies of tissues, and by evidence that development of atherosclerosis is associated with a phenotypic change of VSM from a contractile to a proliferating ('synthetic') phenotype (Orr *et al*., [@b32]) similar to that of VSM in culture (House *et al*., [@b22]).

In the present study, we demonstrate that in human aortic smooth muscle cells (ASMCs), activation of H~1~ receptors by histamine stimulates an increase in intracellular free Ca^2+^ concentration (\[Ca^2+^\]~i~) entirely via activation of inositol 1,4,5-trisphosphate (IP~3~) receptors. Activation of EP~2~ or EP~4~ receptors substantially attenuates the Ca^2+^ signals evoked by histamine, but EP~2~ receptors are largely responsible for the inhibition of Ca^2+^ signals and stimulation of AC activity by PGE~2~.

Methods
=======

Culture of human ASMCs
----------------------

Human ASMCs were purchased from the American Tissue Culture Collection (ATCC, Manassas, VA, USA) or provided by Dr Trevor Littlewood (Division of Cardiovascular Medicine, University of Cambridge) (Boyle *et al*., [@b9]). Ethical committee approval for the latter was obtained from the Addenbrooke\'s NHS Trust. All cells were isolated from patients who died of causes unrelated to the cardiovascular system. Further details of the cells and the specific experiments for which they were used are provided in Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}. Cells were cultured in DMEM supplemented with GlutaMAX-I, heat-inactivated FBS (10%), penicillin (100 units·mL^−1^) and streptomycin (0.1 mg·mL^−1^) at 37°C in humidified air containing 5% CO~2~. Cells from ATCC were first cultured according to the supplier\'s instructions (in ATCC vascular cell basal medium supplemented with ATCC VSM growth kit), and then as described earlier before use in experiments. Cells were used between passages 2 and 6, during which they retained an elongated shape and immunostained for α-smooth muscle actin (not shown).

Measurement of \[Ca^2+^\]~i~ in cell populations
------------------------------------------------

Confluent cultures of ASMC grown in 96-well plates were loaded in HEPES-buffered saline (HBS) with fluo-4 by incubation (1 h, 20°C) with fluo-4-acetoxymethyl ester (4 μM, Invitrogen, Paisley, UK), probenecid (2.5 mM) and pluronic F127 (0.02%, v/v) (Govindan *et al*., [@b19]). After a further incubation (30 min) in HBS supplemented with only probenecid, the medium was replaced with HBS and the cells were used for experiments. HBS had the following composition (mM): NaCl 135, KCl 5.9, MgCl~2~ 1.2, CaCl~2~ 1.5, glucose 11.5 and HEPES 11.6 (pH 7.3). Fluorescence (excitation at 485 nm, emission at 525 nm) was recorded during appropriate additions using a FlexStation 3 fluorescence spectrometer (MDS Analytical Technologies, Wokingham, UK). Fluorescence signals (*F*) were calibrated to \[Ca^2+^\]~i~ from \[Ca^2+^\]~i~ = *K*~D~(*F* − *F*~min~)/(*F*~max~ − *F*), where *K*~D~ is the equilibrium dissociation constant of fluo-4 for Ca^2+^ (345 nM) (Gee *et al*., [@b17]), *F*~min~ is the fluorescence of Ca^2+^-free indicator \[recorded from cells treated with 0.05% Triton X-100 and 10 mM 1,2-bis(2-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid (BAPTA) in Ca^2+^-free HBS\] and *F*~max~ is the fluorescence of Ca^2+^-saturated indicator (cells treated with 0.05% Triton X-100 and 10 mM CaCl~2~ in HBS). Ca^2+^ signals were recorded after addition of histamine alone or in the presence of additional drugs added 5 min before histamine. Further details are provided in the figure legends.

Measurement of AC activity
--------------------------

Two assays were used to determine AC activity in confluent cultures of ASMC. A HitHunter cAMP HS+ (DiscoveRx, Birmingham, UK) enzyme complementation assay was used for most analyses. Briefly, confluent cultures of ASMC in 96-well plates were washed twice with HBS and incubated with appropriate stimuli (5 min). Reactions were stopped by aspirating the medium followed by addition of ice-cold ethanol (100 μL). After 10 min, the ethanol was evaporated (60°C, 30 min). This heating step also inactivates an endogenous β-galactosidase-like activity that otherwise contributes to the final luminescence measurement. The cAMP contents of the extracts were then determined according to the manufacturer\'s instructions. Because the AC inhibitors used \[1 mM SQ 22536 with 200 μM DDA (SQ/DDA)\] interfere with the HitHunter assay, analysis of their effects used a ^3^H-adenine-labelling assay in which cultures of ASMC in 24-well plates were incubated with \[2,8-^3^H\] adenine (1 μCi·mL^−1^, 1 mL per well) in DMEM for 2 h at 37°C in humidified air containing 5% CO~2~. After washing twice with HBS, cells in HBS at 20°C were used for experiments. Incubations were terminated by aspirating the medium and then adding ice-cold trichloroacetic acid (5% v/v, 1 mL). After 30 min at 4°C, ^3^H-labelled adenine nucleotides were separated using sequential Dowex 50WX4-400 (Bio-Rad, Hemel Hampstead, UK) and alumina columns (Sigma-Aldrich, Poole, UK) (Salomon *et al*., [@b37]).

Analyses of EP receptor expression by quantitative PCR (QPCR)
-------------------------------------------------------------

Confluent cultures of human ASMC in 24-well plates were lysed with Fastlane cDNA kit (500 μL per well, Qiagen, Crawley, UK). QPCR reactions were conducted according to the manufacturer\'s instructions using Rotorgene SYBR green PCR kit (Qiagen) with an initial denaturation (95°C, 5 min) followed by 40 cycles of amplification (95°C for 5 s and 60°C for 10 s). Fluorescence was measured at the end of each cycle (Govindan *et al*., [@b19]). Primers specific for EP~2~ (Qiagen Quantitect Primer Assay, code: Hs_PTGER2_1\_SG; Qiagen) or EP~4~ receptors (Hs_PTGER4_2\_SG) or, for calibration, primers for GAPDH (forward, ACCACAGTCCATGCCATCAC; reverse, TCCACCACCCTGTTGCTGTA) were used. The authenticity of each PCR product was confirmed by melting-curve analysis. Amplification efficiency (*E*) was calculated as 10*^m^*, where *m* is the average increase in fluorescence for four cycles after the cycle threshold (*C*~T~). Expression levels relative to the housekeeping product (GAPDH) were calculated from

Reactions were performed in duplicate with extracts from at least three different wells for each patient.

Statistical analysis
--------------------

Concentration--effect relationships were individually fitted by non-linear curve fitting to Hill equations (GraphPad Prism version 5; GraphPad Software, La Jolla, CA, USA). Antagonist affinities (pK~D~) were calculated from dose ratios. Two-tailed paired Student\'s *t*-test or one-way [anova]{.smallcaps} with Bonferroni\'s *post hoc* test was used as appropriate, with *P* \< 0.05 considered significant.

Materials
---------

Cell culture materials, except FBS (Sigma), were from Invitrogen. Ionomycin, U73122 (1-\[6-\[\[(17*β*)-3-methoxyestra-1,3,5(10)-trien-17-yl\]amino\]hexyl\]-1*H*-pyrrole-2,5-dione), U73343 (1-\[6-\[\[(17*β*)-3-methoxyestra-1,3,5(10)-trien-17-yl\]amino\]hexyl\]-2,5-pyrrolidinedione), SQ 22536 (9-(tetrahydro-2-furanyl)-9*H*-purin-6-amine) and DDA (2′,5′-dideoxyadenosine) were from Merck Chemicals Ltd. (Nottingham, UK). *trans-*Ned-19 \[(1*R*,3*S*)-1-\[3-\[\[4-(2-fluorophenyl)piperazin-1-yl\]methyl\]-4-methoxyphenyl\]-2,3,4,9-tetrahydro-1*H*-pyrido\[3,4-*b*\]indole-3-carboxylic acid\] was from Enzo Life Sciences (Exeter, UK). Thapsigargin was from Alomone Labs Ltd. (Jerusalem, Israel). Histamine dihydrochloride, cimetidine hydrochloride, mepyramine maleate, AH6809 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid), BW 245C \[(4*S*)-(3-\[(3*R*,*S*)-3-cyclohexyl-3-hydroxypropyl\]-2,5-dioxo)-4-imidazolidineheptanoic acid\], 2-APB (2-aminoethoxydiphenyl borate) and PGE~2~ were from Sigma. Butaprost (free acid), GW627368X (2-\[4-(4,9-diethoxy-3-oxo-1*H*-benzo\[f\]isoindol-2-yl)phenyl\]-*N*-phenylsulfonylacetamide), latanoprost (free acid) and L902,688 (5-\[(1*E*,3*R*)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl\]-1-\[6-(2*H*-tetrazol-5*R*-yl)hexyl\]-2-pyrrolidinone) were from Cayman Chemicals (Ann Arbor, MI, USA). Indomethacin and sulprostone were from R&D Systems (Minneapolis, MN, USA). Ryanodine was from AbCam (Cambridge, UK). \[2,8-^3^H\] adenine (36 Ci·mmol^−1^) was from PerkinElmer (Seer Green, Bucks, UK). All other reagents were from Sigma or sources specified in the relevant Methods section. Where dimethyl sulphoxide was used as a solvent (usually 0.01% v/v; 0.1% and 0.5% v/v in Figure [1](#fig01){ref-type="fig"}F,E respectively), it was also included in controls. Key properties of the drugs used are provided in Supporting Information [Table S2](#SD1){ref-type="supplementary-material"}. The nomenclature of receptors and ligands follows Alexander *et al*. ([@b2]).

![Histamine H~1~ receptors stimulate an increase in \[Ca^2+^\]~i~ via IP~3~. (A) Histamine (100 μM, bar) stimulates an increase in \[Ca^2+^\]~i~ in populations of ASMC incubated in HBS or Ca^2+^-free HBS. Results show means ± SEM from three wells on a single 96-well plate and are typical of results from four independent plates. (B) Concentration-dependent effects of histamine on the peak \[Ca^2+^\]~i~ in the presence or absence of extracellular Ca^2+^, and on the sustained Ca^2+^ entry (measured ∼230 s after histamine addition). Results are means ± SEM from four independent plates, with one to three wells on each plate. (C) Effect of mepyramine (0.5 μM) and cimetidine (50 μM), each added 5 min before histamine, on histamine-evoked Ca^2+^ signals. Results are means ± SEM from nine independent plates, with one to three wells on each plate. (D) Effects of the indicated concentrations of U73122 and U73343 (added 5 min before histamine) on the peak increase in \[Ca^2+^\]~i~ evoked by histamine (100 μM). Results are means ± SEM from three independent plates, with two wells on each plate. (E) Effects of *trans*-Ned-19 (1 μM) and ryanodine (100 μM), each added 5 min before histamine, on the peak increase in \[Ca^2+^\]~i~ evoked by histamine. Results (percentage of the maximal response) are means ± SEM from three independent plates with one to three wells on each plate. (F) Effect of indomethacin (10 μM, added 5 min before histamine) on the peak Ca^2+^ signals evoked by histamine. Results are means ± SEM from four independent plates, each with three wells. (B--F) Ct denotes control.](bph0169-1624-f1){#fig01}

Results
=======

Histamine H~1~ receptors evoke Ca^2+^ signals via IP~3~ receptors in human ASMCs
--------------------------------------------------------------------------------

Histamine evoked a concentration-dependent increase in \[Ca^2+^\]~i~ in populations of human ASMC. Removal of extracellular Ca^2+^ had no effect on the initial peak response to histamine, but it abolished the very small sustained increase in \[Ca^2+^\]~i~ (Figure [1](#fig01){ref-type="fig"}A,B). The two phases of the Ca^2+^ signal, Ca^2+^ release from intracellular stores (pEC~50~ = 6.56 ± 0.09, *n* = 4) and Ca^2+^ entry (pEC~50~ = 6.12 ± 0.30, *n* = 4), were similarly sensitive to histamine. Responses to histamine were unaffected by cimetidine (50 μM, 5 min), a selective antagonist of H~2~ histamine receptors, but mepyramine (0.5 μM, 5 min), a competitive antagonist of H~1~ histamine receptors (Alexander *et al*., [@b2]), shifted the concentration--effect relationship to ∼26 000-fold higher concentrations of histamine, suggesting a pK~D~ for mepyramine of ∼10.7 (Figure [1](#fig01){ref-type="fig"}C). Pre-equilibration with mepyramine, which dissociates slowly from H~1~ histamine receptors, and the need to measure acute responses to histamine probably exaggerate the effect the antagonist would have at equilibrium, but the results are consistent with histamine, evoking Ca^2+^ signals via a receptor with high affinity for mepyramine and undetectable affinity for cimetidine. U73122, an inhibitor of PLC (Bleasdale *et al*., [@b7]), caused a concentration-dependent inhibition (pIC~50~ = 5.76 ± 0.09, *n* = 3) of the Ca^2+^ signals evoked by histamine, while its inactive analogue, U73343 (≤10 μM), had no effect (Figure [1](#fig01){ref-type="fig"}D).

Similar results, although with slightly different sensitivities to histamine and peak Ca^2+^ signals, were obtained with ASMC isolated from different patients (Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}). These differences, presumably arising from different levels of expression of H~1~ receptors or downstream signalling proteins, highlight the need for paired comparisons of experimental manipulations in subsequent analyses of human ASMC. It also justifies our presentation of some results as percentages of matched control responses.

There are no membrane-permeant selective antagonists of IP~3~ receptors, although 2-APB has often been used (Taylor and Tovey, [@b45]). 2-APB caused a concentration-dependent inhibition of the Ca^2+^ signals evoked by either maximally or submaximally effective concentrations of histamine (Supporting Information [Figure S2A--D](#SD1){ref-type="supplementary-material"}). However, in keeping with published results (Peppiatt *et al*., [@b33]), similar concentrations of 2-APB also caused a substantial loss of Ca^2+^ from the intracellular stores (Supporting Information [Figure S2E,F](#SD1){ref-type="supplementary-material"}). While the slightly greater sensitivity of the histamine responses to 2-APB is consistent with the expected involvement of IP~3~ receptors, the results highlight the limitations of 2-APB as a useful antagonist of IP~3~ receptors.

Ryanodine receptors and the intracellular Ca^2+^ channels that are activated by nicotinic acid adenine dinucleotide phosphate (NAADP), probably two-pore channels (Calcraft *et al*., [@b12]), can also mediate Ca^2+^ release from intracellular stores, including those of VSM (Boittin *et al*., [@b8]; Tugba Durlu-Kandilci *et al*., [@b47]). However, caffeine (10 mM), which activates ryanodine receptors, had no effect on \[Ca^2+^\]~i~ (Supporting Information [Figure S3A](#SD1){ref-type="supplementary-material"}), and the responses to histamine were unaffected by concentrations of either *trans*-Ned-19 (1 μM, 5 min) that block responses to NAADP (Naylor *et al*., [@b30]; Brailoiu *et al*., [@b10]) or of ryanodine (100 μM, 5 min) that block ryanodine receptors (Zheng *et al*., [@b54]) (Figure [1](#fig01){ref-type="fig"}E).

These results demonstrate that activation of H~1~ receptors by histamine stimulates Ca^2+^ release via IP~3~ receptors in human ASMC, and that neither ryanodine receptors nor two-pore channels contribute to the response. Our results are consistent with widespread expression of H~1~ histamine receptors in most smooth muscles (Hill *et al*., [@b21]) and with evidence that histamine, via H~1~ receptors, stimulates PLC and an increase in \[Ca^2+^\]~i~ in human ASMC (Satoh *et al*., [@b39]). In light of subsequent evidence demonstrating effects of PGE~2~ and cAMP on Ca^2+^ signals, we considered the possibility that histamine might influence Ca^2+^ signals via activation of endogenous H~2~ receptors or stimulate production of endogenous prostanoids. However, neither cimetidine, a selective antagonist of H~2~ receptors (Figure [1](#fig01){ref-type="fig"}C), nor indomethacin, an inhibitor of cyclooxygenases (Figure [1](#fig01){ref-type="fig"}F), had any effect on histamine-evoked Ca^2+^ signals in human ASMC.

PGE~2~ inhibits histamine-evoked Ca^2+^ signals
-----------------------------------------------

PGE~2~ alone had no effect on \[Ca^2+^\]~i~ (Supporting Information [Figure S3B](#SD1){ref-type="supplementary-material"}), but the Ca^2+^ signals evoked by histamine (100 μM) were attenuated by PGE~2~ (10 μM, 5 min) (Figure [2](#fig02){ref-type="fig"}A). PGE~2~ decreased the sensitivity of ASMC to histamine (pEC~50~ = 6.32 ± 0.10 and 5.74 ± 0.12, *n* = 7, in control and PGE~2~-treated cells respectively) and it reduced the maximal response by 51 ± 2% (Figure [2](#fig02){ref-type="fig"}B). PGE~2~ had similar effects on both phases of the Ca^2+^ signal: Ca^2+^ release and the small Ca^2+^ entry (Figure [2](#fig02){ref-type="fig"}C). The effects of PGE~2~ on the peak increase in \[Ca^2+^\]~i~ evoked by histamine (3 μM) were concentration dependent (pIC~50~ = 8.99 ± 0.10, *n* = 15; Figure [2](#fig02){ref-type="fig"}D). Similar results, although again with some variation in absolute sensitivities, were obtained from different patients (Supporting Information [Figure S1 and Table S3](#SD1){ref-type="supplementary-material"}). PGE~2~ (10 μM) did not affect the Ca^2+^ content of the intracellular stores whether assessed by addition, in Ca^2+^-free HBS, of thapsigargin or cyclopiazonic acid to inhibit the Ca^2+^ pump (SERCA) of the sarcoplasmic reticulum (SR), or of ionomycin to release Ca^2+^ directly (Figure [2](#fig02){ref-type="fig"}E). These results demonstrate that PGE~2~ causes a concentration-dependent inhibition of the Ca^2+^ signals evoked by activation of H~1~ histamine receptors without affecting the Ca^2+^ content of the SR.

![PGE~2~ inhibits histamine-evoked Ca^2+^ release. (A) Ca^2+^ signals evoked by histamine (100 μM, bar) alone or with PGE~2~ (10 μM, added 5 min before and then with histamine). Results, means ± SEM from three wells on a single plate, are typical of results from four independent plates. (B) Effect of PGE~2~ (10 μM) on the peak Ca^2+^ signals evoked by the indicated concentrations of histamine. Results are means ± SEM from seven independent plates, each with one to three wells. (C) Effect of PGE~2~ on the sustained Ca^2+^ signals evoked by histamine. Results are means ± SEM from 11 independent plates, each with one to three wells. (D) Effect of the indicated concentrations of PGE~2~ (added 5 min before histamine) on the peak increase in \[Ca^2+^\]~i~ evoked by histamine (3 μM). Results are means ± SEM from 15 independent plates, with one to three wells analysed from each. (B--D) Ct denotes control. Similar results from ASMC isolated from different patients are shown in Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}. (E) Effects of pretreatment with PGE~2~ (10 μM, 5 min) on the peak Ca^2+^ signals evoked by subsequent addition of thapsigargin (1 μM), cyclopiazonic acid (10 μM) or ionomycin (1 μM) to ASMC in Ca^2+^-free HBS. Results (as percentages of the responses obtained without PGE~2~) are means ± SEM from three independent plates, with seven wells analysed on each.](bph0169-1624-f2){#fig02}

Activation of EP~2~ or EP~4~ receptors inhibits histamine-evoked Ca^2+^ signals
-------------------------------------------------------------------------------

PGE~2~ activates many prostanoid receptors, with EP~1--4~, DP~1~ and FP receptors being the most sensitive (Abramovitz *et al*., [@b1]; Alexander *et al*., [@b2]). EP~1~ receptors cannot mediate inhibition of histamine-evoked Ca^2+^ signals because their coupling to Gq would be expected to increase \[Ca^2+^\]~i~. Sulprostone binds selectively to EP~3~ receptors, with an affinity similar to that of PGE~2~. BW 245C and latanoprost are selective high-affinity agonists of DP~1~ and FP receptors respectively (Abramovitz *et al*., [@b1]) (Supporting Information [Table S2](#SD1){ref-type="supplementary-material"}). Sulprostone (1 μM), BW 245C (10 nM) and latanoprost (100 nM) had no effect on histamine-evoked Ca^2+^ signals (Supporting Information [Figure S3C](#SD1){ref-type="supplementary-material"}), suggesting that neither EP~3~, DP~1~ nor FP receptors contribute to the inhibition of Ca^2+^ signals by PGE~2~. Subsequent experiments therefore assess the contributions of EP~2~ and EP~4~ receptors, both of which are expressed in human VSM (Qian *et al*., [@b35]; Bayston *et al*., [@b4]; Davis *et al*., [@b14]; Foudi *et al*., [@b15]).

QPCR analysis of ASMC from two patients established that transcripts for EP~2~ and EP~4~ receptors were expressed at similar levels. In patients a and d (Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}), 48 ± 2% and 59 ± 1% of the transcripts were for the EP~2~ receptor. Although we have not directly assessed protein expression, the results are consistent with comparable levels of expression of EP~2~ and EP~4~ receptors in human ASMC.

Butaprost, a selective agonist of EP~2~ receptors (Sugimoto and Narumiya, [@b41]; Alexander *et al*., [@b2]), caused a concentration-dependent inhibition of the Ca^2+^ signals evoked by 3 μM histamine (pIC~50~ = 8.22 ± 0.05, *n* = 3) (Figure [3](#fig03){ref-type="fig"}A, Table [1](#tbl1){ref-type="table"}). AH6809 is a poorly selective low-affinity antagonist of EP~2~ receptors (pK~D~ = 5.9), but it does not interact with EP~4~ receptors (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}). The response to butaprost was competitively antagonized by AH6809 (30 μM, ΔpIC~50~ = 1.12 ± 0.15, where ΔpIC~50~ = pIC~50~^control^ − pIC~50~^+antagonist^), but insensitive to GW627368X (1 μM, ΔpIC~50~ = −0.21 ± 0.14), an antagonist of EP~4~ receptors (Wilson *et al*., [@b50]) (Figure [3](#fig03){ref-type="fig"}A, Table [1](#tbl1){ref-type="table"}). These results show that butaprost inhibits histamine-evoked Ca^2+^ signals via a receptor with an affinity (pK~D~) for AH6809 of 5.6. This confirms that the inhibition is mediated by EP~2~ receptors (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}).

![Activation of EP~2~ or EP~4~ receptors inhibits histamine-evoked Ca^2+^ signals. (A, B) Effect of butaprost (A, 5 min) or L902,688 (B, 5 min) on the Ca^2+^ signals evoked by histamine (3 μM) alone or in the presence of AH6809 (30 μM, 5 min) or GW627368X (1 μM, 5 min). Results (means ± SEM from three independent plates, with two wells analysed from each) show amplitudes of the peak changes in \[Ca^2+^\]~i~ evoked by histamine. Ct denotes control. Summary results are shown in Table [1](#tbl1){ref-type="table"}.](bph0169-1624-f3){#fig03}

###### 

Effects of PGE~2~ and selective ligands of EP~2~ and EP~4~ receptors on histamine-evoked Ca^2+^ signals and cAMP accumulation

                                \[Ca^2+^\]~i~, pIC~50~ (/M)                                                                           cAMP, pEC~50~ (/M)
  ----------- ----------------- -------------------------------------------------- -------------------------------------------------- --------------------
  PGE~2~      9.27 ± 0.12 (4)   8.65 ± 0.07[\*](#tf1-1){ref-type="table-fn"} (4)   9.03 ± 0.13 (4)                                    6.62 ± 0.10 (4)
  Butaprost   8.22 ± 0.05 (3)   7.10 ± 0.19[\*](#tf1-1){ref-type="table-fn"} (3)   8.43 ± 0.17 (3)                                    5.68 ± 0.09 (4)
  L902,688    9.52 ± 0.25 (3)   9.53 ± 0.05 (3)                                    7.31 ± 0.21[\*](#tf1-1){ref-type="table-fn"} (3)   7.76 ± 0.11 (3)

Concentration-dependent effects of the indicated agonists of EP receptors on the increase in \[Ca^2+^\]~i~ evoked by histamine (3 μM) (pIC~50~) or cAMP accumulation (pEC~50~) are shown alone or in the presence of antagonists of EP~2~ (AH6809, 30 μM) or EP~4~ (GW627368X, 1 μM) receptors. Measurements of cAMP accumulation were performed using the HitHunter HS+ assay. Results are means ± SEM, with the number of independent experiments shown in parentheses.

*P* \< 0.05 relative to control.

L902,688 is a selective agonist of EP~4~ receptors with slightly greater affinity than PGE~2~ (Young *et al*., [@b53]) (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}). L902,688 also caused a concentration-dependent inhibition of histamine-evoked Ca^2+^ signals (pIC~50~ = 9.52 ± 0.25, *n* = 3) (Figure [3](#fig03){ref-type="fig"}B, Table [1](#tbl1){ref-type="table"}). This inhibition was insensitive to AH6809 (30 μM, ΔpIC~50~ = −0.01 ± 0.27), but competitively inhibited by GW627368X (1 μM, ΔpIC~50~ = 2.20 ± 0.28). The latter suggests that L902,688 acts via a receptor with an affinity (pK~D~) for GW627368X of 8.2, consistent with it being an EP~4~ receptor (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}). We conclude that selective activation of either EP~2~ or EP~4~ receptors in human ASMC inhibits histamine-evoked Ca^2+^ release. For butaprost, the sensitivity of the functional response (pIC~50~ = 8.22) and the published binding affinity (pK~D~ = 7.04) differ by more than 10-fold, whereas they are more similar for L902,688 (9.5 and 9.4 respectively). This suggests that for inhibition of histamine-evoked Ca^2+^ signals, there is a greater receptor reserve for EP~2~, than for EP~4~, receptors.

PGE~2~ inhibits histamine-evoked Ca^2+^ signals largely via EP~2~ receptors
---------------------------------------------------------------------------

Maximally effective concentrations of PGE~2~, butaprost or L902,688, caused similar inhibition of histamine-evoked Ca^2+^ signals, and no combination of the three stimuli caused any greater inhibition than a single stimulus (Figure [4](#fig04){ref-type="fig"}A,B). This suggests that the three stimuli converge to cause inhibition via a common pathway. Subsequent experiments resolve which of the two receptors (EP~2~ or EP~4~) mediates the response to the endogenous stimulus, PGE~2~.

![PGE~2~ inhibits histamine-evoked Ca^2+^ signals largely via EP~2~ receptors. (A) Effect of PGE~2~ (10 μM) alone or in combination with butaprost and L902,688 (10 μM each) on the peak Ca^2+^ signals evoked by the indicated concentrations of histamine. Results are means ± SEM from three independent plates, each with one to two wells. (B) Peak Ca^2+^ signals evoked by histamine (3 μM) alone or with (5 min) PGE~2~ (10 μM), butaprost (100 μM), L902,688 (10 μM) or the indicated combinations. Results are means ± SEM from 11 to 14 wells. (C) Effect of PGE~2~ (5 min) on the peak Ca^2+^ signals evoked by histamine (3 μM) alone or in the presence of AH6809 (30 μM, 5 min) or GW627368X (1 μM, 5 min). Results are means ± SEM from four independent plates, each with one to two wells. (A, C) Ct denotes control. (D) ΔpIC~50~ values for PGE~2~, butaprost and L902,688 and the antagonists of EP~2~ (AH6809, 30 μM) or EP~4~ (GW627368X, 1 μM) receptors. Results are means ± SEM from three to four independent experiments.](bph0169-1624-f4){#fig04}

Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ (pIC~50~ = 9.27 ± 0.12, *n* = 4) was antagonized by AH6809 (30 μM, ΔpIC~50~ = 0.62 ± 0.13), but to a lesser extent than the response to butaprost (ΔpIC~50~ = 1.12 ± 0.15). GW627368X (1 μM) also inhibited the responses to PGE~2~ (ΔpIC~50~ = 0.24 ± 0.08), but to a much lesser degree than the response to L902,688 (ΔpIC~50~ = 2.20 ± 0.28) (Figure [4](#fig04){ref-type="fig"}C, Table [1](#tbl1){ref-type="table"}). These results suggest that both EP~2~ and EP~4~ receptors contribute to the PGE~2~-mediated inhibition of histamine-evoked Ca^2+^ signals, but the magnitudes of the disparities between the effects of the competitive antagonists on responses to PGE~2~ and those evoked by the subtype-selective agonists (Figure [4](#fig04){ref-type="fig"}D) suggest that EP~2~ receptors mediate most responses to PGE~2~. EP~4~ receptors bind PGE~2~ with approximately sixfold greater affinity than EP~2~ receptors (Abramovitz *et al*., [@b1]). The predominant role of the latter must, therefore, be due to their greater expression or more effective coupling to downstream signalling, consistent with our suggestion that only EP~2~ receptors have a receptor reserve. Our evidence that transcripts for EP~2~ and EP~4~ receptors are expressed at similar levels would be consistent with more effective coupling of EP~2~ receptors.

EP~2~ and EP~4~ receptors differ in their abilities to stimulate AC
-------------------------------------------------------------------

Because EP~2~ and EP~4~ receptors share an ability to activate AC via the G protein Gs (Alexander *et al*., [@b2]), we examined the effects of their activation on cAMP accumulation in human ASMC. PGE~2~ evoked a concentration-dependent accumulation of cAMP whether assessed using ^3^H-adenine labelling (pEC~50~ = 6.67 ± 0.06, *n* = 3) or the HitHunter assay (pEC~50~ = 6.62 ± 0.10, *n* = 4) (Figure [5](#fig05){ref-type="fig"}). This stimulation of cAMP accumulation was reduced by 83 ± 1% (*n* = 3) in the presence of inhibitors of AC, SQ 22536 (1 mM) and DDA (200 μM) (hereafter described as SQ/DDA) (Figure [5](#fig05){ref-type="fig"}B). We note that as with histamine-evoked Ca^2+^ signals, there was a variability between patients and cell passages in the absolute amounts of cAMP produced in response to PGE~2~, again dictating the need for paired comparisons of treatments (Table [1](#tbl1){ref-type="table"}). These results are consistent with an earlier report in which PGE~2~, but not histamine, evoked an increase in cAMP in human ASMC (Satoh *et al*., [@b39]). Butaprost also stimulated AC activity (pEC~50~ = 5.68 ± 0.09, *n* = 4; Figure [5](#fig05){ref-type="fig"}A, Table [1](#tbl1){ref-type="table"}). The similar maximal effects of PGE~2~ and butaprost, and the ∼10-fold higher EC~50~ of the latter, are consistent with evidence that butaprost is a full agonist of human EP~2~ receptors with ∼20-fold lower affinity than PGE~2~ (Narumiya *et al*., [@b29]; Abramovitz *et al*., [@b1]) (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}).

![PGE~2~ stimulates AC predominantly via EP~2~ receptors. (A) Effects of the indicated concentrations of PGE~2~, butaprost and L902,688 (5 min) on cAMP formation measured using a HitHunter assay. (B) Effect of PGE~2~ (5 min) on cAMP accumulation (determined using ^3^H-adenine labelling, and expressed as percentages of ^3^H-ATP + ^3^H-ADP) alone or after treatment with SQ 22536 (1 mM SQ) alone (*n* = 1) or SQ 22536 with DDA (200 μM) (*n* = 3). Both inhibitors were added 20 min before and then during stimulation with PGE~2~. Results (except for SQ alone in panel B) are means ± SEM from three to four independent plates. Ct denotes control.](bph0169-1624-f5){#fig05}

L902,688, which has approximately twofold greater affinity than PGE~2~ for EP~4~ receptors (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}), stimulated a concentration-dependent (pEC~50~ = 7.76 ± 0.11) accumulation of cAMP that was only 32 ± 2% (*n* = 3) of that evoked by a maximally effective concentration of PGE~2~ (Figure [5](#fig05){ref-type="fig"}A). The lesser maximal response to L902,688 and greater sensitivity relative to PGE~2~ (Figure [5](#fig05){ref-type="fig"}A) suggest that EP~4~ receptors probably mediate the effect of L902,688 on AC activity (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}). We suggest that both EP~2~ and EP~4~ receptors stimulate AC in human ASMC, but the former is either more abundant or more effectively coupled to AC, and largely mediates the effects of PGE~2~. More effective coupling of EP~2~ receptors would be consistent with our analysis of transcripts for EP~2~ and EP~4~ receptors, and with analyses showing that EP~2~ receptors evoke greater stimulation of AC than do EP~4~ receptors when each is heterologously expressed at a similar level (Fujino *et al*., [@b16]).

Discussion
==========

Activation of histamine H~1~ receptors evokes an increase in \[Ca^2+^\]~i~ in human ASMC that results from Ca^2+^ release via IP~3~ receptors, followed by a small sustained response mediated by Ca^2+^ entry, most likely via a store-operated Ca^2+^ entry pathway (Figure [1](#fig01){ref-type="fig"}). Such biphasic Ca^2+^ signals are typical of those evoked by PLC-coupled receptors in VSM (Berridge, [@b6]) and other tissues (Putney, [@b34]). PGE~2~ is another inflammatory mediator with widespread actions in the vasculature (Norel, [@b31]). The receptors through which PGE~2~ regulates human ASMC have not hitherto been defined, although both EP~2~ and EP~4~ receptors mediate relaxation and/or attenuation of Ca^2+^ signalling in other human smooth muscles (Baxter *et al*., [@b3]; Jones *et al*., [@b25]; Benyahia *et al*., [@b5]).

We have shown that in human ASMC, PGE~2~ attenuates histamine-evoked Ca^2+^ signals without affecting the Ca^2+^ content of the intracellular stores (Figure [2](#fig02){ref-type="fig"}). This inhibition is mediated by cAMP (Pantazaka *et al*., unpubl. obs.). Inhibition of histamine-evoked Ca^2+^ signals is mimicked by selective activation of either EP~2~ or EP~4~ receptors (Figures [3](#fig03){ref-type="fig"} and [4](#fig04){ref-type="fig"}A--C), but results with selective antagonists suggest that EP~2~ receptors predominantly mediate the effect of PGE~2~ on \[Ca^2+^\]~i~ (Figure [4](#fig04){ref-type="fig"}D). This is consistent with the relationships between pIC~50~ and published K~D~ values for the subtype-selective agonists suggesting a greater receptor reserve for EP~2~ receptors. It also aligns with evidence that both EP~2~ and EP~4~ receptors stimulate AC activity, but the maximal response is much larger for EP~2~ receptors (Figure [5](#fig05){ref-type="fig"}A). The predominant role of EP~2~, relative to EP~4~, receptors, despite the lower *K*~D~ of the latter (Supporting Information [Table S4](#SD1){ref-type="supplementary-material"}), could arise from higher levels of expression of EP~2~ receptors in human ASMC or their more effective coupling to stimulation of AC (Fujino *et al*., [@b16]). The latter seems more likely because transcripts for EP~2~ and EP~4~ receptors are expressed at similar levels in human ASMC. There is some evidence that functional EP receptors, including EP~2~ and EP~4~ receptors, are expressed in both the plasma membrane and the nuclear envelope of some cells (Zhu *et al*., [@b55]). We have not assessed whether this contributes to the ability of PGE~2~ to inhibit histamine-evoked Ca^2+^ signals.

Our results demonstrate that two important inflammatory mediators, histamine and PGE~2~, acting via receptors that are targets of existing clinically approved drugs, interact to control \[Ca^2+^\]~i~ in human ASMC. EP~2~, EP~4~ and histamine H~1~ receptors might thereby provide effective therapeutic targets for treatment of atherosclerosis.
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2-APB

:   2-aminoethoxydiphenyl borate

AC

:   adenylyl cyclase

AH6809

:   6-isopropoxy-9-oxoxanthene-2-carboxylic acid

ASMC

:   aortic smooth muscle cell

BW 245C

:   (4*S*)-(3-\[(3*R*,*S*)-3-cyclohexyl-3-hydroxypropyl\]-2,5-dioxo)-4-imidazolidineheptanoic acid

\[Ca^2+^\]~i~

:   intracellular free Ca^2+^ concentration

DDA

:   2′,5′-dideoxyadenosine

GW627368X

:   2-\[4-(4,9-diethoxy-3-oxo-1*H*-benzo\[f\]isoindol-2-yl)phenyl\]-*N*-phenylsulfonylacetamide

HBS

:   HEPES-buffered saline

IP~3~

:   inositol 1,4,5-trisphosphate

L902,688

:   5-\[(1*E*,3*R*)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl\]-1-\[6-(2*H*-tetrazol-5*R*-yl)hexyl\]-2-pyrrolidinone

NAADP

:   nicotinic acid adenine dinucleotide phosphate

pEC~50~ (pIC~50~)

:   negative logarithm of the half-maximally effective (inhibitory) concentration

PLC

:   phospholipase C

SQ 22536

:   9-(tetrahydro-2-furanyl)-9*H*-purin-6-amine

SQ/DDA

:   1 mM SQ 22536 with 200 μM DDA (used to inhibit AC)

SR

:   sarcoplasmic reticulum

*trans*-Ned-19

:   (1*R*,3*S*)-1-\[3-\[\[4-(2-fluorophenyl)piperazin-1-yl\]methyl\]-4-methoxyphenyl\]-2,3,4,9-tetrahydro-1*H*-pyrido\[3,4-*b*\]indole-3-carboxylic acid

U73122

:   1-\[6-\[\[(17*β*)-3-methoxyestra-1,3,5(10)-trien-17-yl\]amino\]hexyl\]-1*H*-pyrrole-2,5-dione

U73343

:   1-\[6-\[\[(17*β*)-3-methoxyestra-1,3,5(10)-trien-17 yl\]amino\]hexyl\]-2,5-pyrrolidinedione

VSM

:   vascular smooth muscle
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**Figure S1** Inhibition of histamine-evoked Ca^2+^ signals by PGE~2~ in ASMC from different patients. (A--C) Peak Ca^2+^ signals evoked by the indicated concentrations of histamine alone or with PGE~2~ (10 μM added 5 min before histamine). Results are from three different patients (codes in Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}) and show means ± SEM from five (A), 15 (B) and 11 (C) independent experiments. (D). Effect of the indicated concentrations of PGE~2~ (added 5 min before histamine) on the pEC~50~ for histamine-evoked peak Ca^2+^ signals. Ct denotes control.

**Figure S2** Inhibition of histamine-evoked Ca^2+^ signals and depletion of intracellular Ca^2+^ stores by 2-APB. (A, C) Effect of 2-APB (added 5 min before histamine) on the Ca^2+^ signals evoked by submaximal (3 μM) (A) or maximal (1 mM) (C) concentrations of histamine in Ca^2+^-free HBS. (E) Similar analyses of the effects of 2-APB on the Ca^2+^ content of the intracellular stores assessed by addition of ionomycin (1 μM). The code shown in panel E applies to all three panels (B, D, F). Summary results show peak Ca^2+^ signals evoked by histamine (B, D) or ionomycin (F) after the indicated treatments with 2-APB. Results (A--F) are means ± SEM from three independent plates, with two wells analysed from each.

**Figure S3** Caffeine and PGE~2~ do not directly affect \[Ca^2+^\]~i~, and neither EP~3~, DP~1~ nor FP receptors contribute to inhibition of Ca^2+^ signals by PGE~2~. (A) Populations of ASMC in HBS were stimulated with caffeine (A, 10 mM) and then histamine (3 μM). (B) In similar experiments, ASMCs were stimulated with histamine alone (3 μM) or after pretreatment with PGE~2~ (10 μM) as shown. The trace shows that although PGE~2~ inhibits histamine-evoked Ca^2+^ signals, it does not itself affect \[Ca^2+^\]~i~. Results (A and B) are means ± SEM from four wells on a single 96-well plate and are typical of results from three independent experiments. (C) The peak increase in \[Ca^2+^\]~i~ evoked by histamine (3 μM) is shown for histamine alone or in the presence of PGE~2~ (100 nM) or agonists selective for EP~3~ receptors (sulprostone, 1 μM), DP~1~ receptors (BW 245C, 10 nM) or FP receptors (latanoprost, 100 nM) (each added 5 min before histamine). Results are means ± SEM from 8--29 wells.

**Table S1** Sources of the human ASMC used.

**Table S2** Key properties of the drugs used.

**Table S3** Attenuation of histamine-evoked Ca^2+^ signals in human ASMC from different patients.

**Table S4** Reported affinities (pK~D~) of drugs used for analysis of EP~2~ and EP~4~ receptors.
